Aripiprazole is a second-generation antipsychotic that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, while functioning as an antagonist at 5-HT2A receptors. In the context of Cluster Headache, it is believed to modulate neurotransmitter signaling and potentially reduce neurogenic inflammation, which may help mitigate the frequency and intensity of headache episodes. Its unique mechanism of action provides a potential alternative treatment strategy for patients with refractory or treatment-resistant Cluster Headache.